2024 ICD-10-PCS Tables |
Back to ICD-10 PCS (Procedure) Home |
The ICD-10-PCS Tables contains all valid codes in table format. The tables are arranged in alphanumeric order, and organized into separate tables according to the first three characters of the seven-character code.
After the first three characters are selected, you will see more lists of combinations of the remaining characters that comprise valid PCS codes. Each such list of combinations is displayed have a title which corresponds to the column headings ("Body Part", "Approach", "Device" and "Qualifier" for section zero).
| Section | X | New Technology |
| Body System | W | Anatomical Regions |
| Operation | 0 | Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
|---|---|---|---|
| 0: Skin |
X: External |
2: Anacaulase-bcdb |
7: New Technology Group 7 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
1: Daratumumab and Hyaluronidase-fihj 4: Teclistamab Antineoplastic |
8: New Technology Group 8 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
9: Satralizumab-mwge |
7: New Technology Group 7 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
F: Other New Technology Therapeutic Substance |
5: New Technology Group 5 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
G: REGN-COV2 Monoclonal Antibody H: Other New Technology Monoclonal Antibody K: Leronlimab Monoclonal Antibody |
6: New Technology Group 6 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
L: Elranatamab Antineoplastic |
9: New Technology Group 9 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
S: COVID-19 Vaccine Dose 1 |
6: New Technology Group 6 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
S: Epcoritamab Monoclonal Antibody |
9: New Technology Group 9 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
T: COVID-19 Vaccine Dose 2 U: COVID-19 Vaccine |
6: New Technology Group 6 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
V: COVID-19 Vaccine Dose 3 |
7: New Technology Group 7 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
W: Caplacizumab |
5: New Technology Group 5 |
| 1: Subcutaneous Tissue |
3: Percutaneous |
W: COVID-19 Vaccine Booster |
7: New Technology Group 7 |
| 1: Subcutaneous Tissue |
X: External |
2: Anacaulase-bcdb |
7: New Technology Group 7 |
| 2: Muscle |
0: Open |
D: Engineered Allogeneic Thymus Tissue |
8: New Technology Group 8 |
| 2: Muscle |
3: Percutaneous |
S: COVID-19 Vaccine Dose 1 T: COVID-19 Vaccine Dose 2 U: COVID-19 Vaccine |
6: New Technology Group 6 |
| 2: Muscle |
3: Percutaneous |
V: COVID-19 Vaccine Dose 3 W: COVID-19 Vaccine Booster X: Tixagevimab and Cilgavimab Monoclonal Antibody Y: Other New Technology Monoclonal Antibody |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
0: Brexanolone |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
0: Spesolimab Monoclonal Antibody |
8: New Technology Group 8 |
| 3: Peripheral Vein |
3: Percutaneous |
2: Nerinitide 3: Durvalumab Antineoplastic |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
5: Narsoplimab Monoclonal Antibody |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
5: Mosunetuzumab Antineoplastic |
8: New Technology Group 8 |
| 3: Peripheral Vein |
3: Percutaneous |
6: Lefamulin Anti-infective |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
6: Terlipressin |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
6: Afamitresgene Autoleucel Immunotherapy |
8: New Technology Group 8 |
| 3: Peripheral Vein |
3: Percutaneous |
7: Coagulation Factor Xa, Inactivated |
2: New Technology Group 2 |
| 3: Peripheral Vein |
3: Percutaneous |
7: Trilaciclib |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
7: Tabelecleucel Immunotherapy |
8: New Technology Group 8 |
| 3: Peripheral Vein |
3: Percutaneous |
8: Lurbinectedin |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
8: Treosulfan |
8: New Technology Group 8 |
| 3: Peripheral Vein |
3: Percutaneous |
9: Ceftolozane/Tazobactam Anti-infective |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
9: Inebilizumab-cdon |
8: New Technology Group 8 |
| 3: Peripheral Vein |
3: Percutaneous |
A: Cefiderocol Anti-infective |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
A: Ciltacabtagene Autoleucel |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
B: Cytarabine and Daunorubicin Liposome Antineoplastic |
3: New Technology Group 3 |
| 3: Peripheral Vein |
3: Percutaneous |
B: Omadacycline Anti-infective |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
B: Amivantamab Monoclonal Antibody |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
C: Eculizumab |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
D: Atezolizumab Antineoplastic |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
E: Remdesivir Anti-infective |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
E: Etesevimab Monoclonal Antibody |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
F: Other New Technology Therapeutic Substance |
3: New Technology Group 3 |
| 3: Peripheral Vein |
3: Percutaneous |
F: Other New Technology Therapeutic Substance |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
F: Bamlanivimab Monoclonal Antibody |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
G: Sarilumab |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
G: REGN-COV2 Monoclonal Antibody |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
H: Tocilizumab |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
H: Other New Technology Monoclonal Antibody |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
H: Axicabtagene Ciloleucel Immunotherapy J: Tisagenlecleucel Immunotherapy |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
K: Fosfomycin Anti-infective |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
K: Idecabtagene Vicleucel Immunotherapy |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
K: Sulbactam-Durlobactam |
9: New Technology Group 9 |
| 3: Peripheral Vein |
3: Percutaneous |
L: CD24Fc Immunomodulator |
6: New Technology Group 6 |
| 3: Peripheral Vein |
3: Percutaneous |
L: Lifileucel Immunotherapy M: Brexucabtagene Autoleucel Immunotherapy |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
N: Meropenem-vaborbactam Anti-infective |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
N: Lisocabtagene Maraleucel Immunotherapy |
7: New Technology Group 7 |
| 3: Peripheral Vein |
3: Percutaneous |
P: Glofitamab Antineoplastic |
9: New Technology Group 9 |
| 3: Peripheral Vein |
3: Percutaneous |
Q: Tagraxofusp-erzs Antineoplastic |
5: New Technology Group 5 |
| 3: Peripheral Vein |
3: Percutaneous |
Q: Posoleucel R: Rezafungin |
9: New Technology Group 9 |
| 3: Peripheral Vein |
3: Percutaneous |
S: Iobenguane I-131 Antineoplastic U: Imipenem-cilastatin-relebactam Anti-infective W: Caplacizumab |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
0: Brexanolone |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
0: Spesolimab Monoclonal Antibody |
8: New Technology Group 8 |
| 4: Central Vein |
3: Percutaneous |
2: Nerinitide 3: Durvalumab Antineoplastic |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
5: Narsoplimab Monoclonal Antibody |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
5: Mosunetuzumab Antineoplastic |
8: New Technology Group 8 |
| 4: Central Vein |
3: Percutaneous |
6: Lefamulin Anti-infective |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
6: Terlipressin |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
6: Afamitresgene Autoleucel Immunotherapy |
8: New Technology Group 8 |
| 4: Central Vein |
3: Percutaneous |
7: Coagulation Factor Xa, Inactivated |
2: New Technology Group 2 |
| 4: Central Vein |
3: Percutaneous |
7: Trilaciclib |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
7: Tabelecleucel Immunotherapy |
8: New Technology Group 8 |
| 4: Central Vein |
3: Percutaneous |
8: Lurbinectedin |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
8: Treosulfan |
8: New Technology Group 8 |
| 4: Central Vein |
3: Percutaneous |
9: Ceftolozane/Tazobactam Anti-infective |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
9: Inebilizumab-cdon |
8: New Technology Group 8 |
| 4: Central Vein |
3: Percutaneous |
A: Cefiderocol Anti-infective |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
A: Ciltacabtagene Autoleucel |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
B: Cytarabine and Daunorubicin Liposome Antineoplastic |
3: New Technology Group 3 |
| 4: Central Vein |
3: Percutaneous |
B: Omadacycline Anti-infective |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
B: Amivantamab Monoclonal Antibody |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
C: Eculizumab |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
D: Atezolizumab Antineoplastic |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
E: Remdesivir Anti-infective |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
E: Etesevimab Monoclonal Antibody |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
F: Other New Technology Therapeutic Substance |
3: New Technology Group 3 |
| 4: Central Vein |
3: Percutaneous |
F: Other New Technology Therapeutic Substance |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
F: Bamlanivimab Monoclonal Antibody |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
G: Sarilumab |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
G: REGN-COV2 Monoclonal Antibody |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
H: Tocilizumab |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
H: Other New Technology Monoclonal Antibody |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
H: Axicabtagene Ciloleucel Immunotherapy J: Tisagenlecleucel Immunotherapy |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
K: Fosfomycin Anti-infective |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
K: Idecabtagene Vicleucel Immunotherapy |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
K: Sulbactam-Durlobactam |
9: New Technology Group 9 |
| 4: Central Vein |
3: Percutaneous |
L: CD24Fc Immunomodulator |
6: New Technology Group 6 |
| 4: Central Vein |
3: Percutaneous |
L: Lifileucel Immunotherapy M: Brexucabtagene Autoleucel Immunotherapy |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
N: Meropenem-vaborbactam Anti-infective |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
N: Lisocabtagene Maraleucel Immunotherapy |
7: New Technology Group 7 |
| 4: Central Vein |
3: Percutaneous |
P: Glofitamab Antineoplastic |
9: New Technology Group 9 |
| 4: Central Vein |
3: Percutaneous |
Q: Tagraxofusp-erzs Antineoplastic |
5: New Technology Group 5 |
| 4: Central Vein |
3: Percutaneous |
Q: Posoleucel R: Rezafungin |
9: New Technology Group 9 |
| 4: Central Vein |
3: Percutaneous |
S: Iobenguane I-131 Antineoplastic U: Imipenem-cilastatin-relebactam Anti-infective W: Caplacizumab |
5: New Technology Group 5 |
| 5: Peripheral Artery |
3: Percutaneous |
T: Melphalan Hydrochloride Antineoplastic |
9: New Technology Group 9 |
| 9: Nose |
7: Via Natural or Artificial Opening |
M: Esketamine Hydrochloride |
5: New Technology Group 5 |
| D: Mouth and Pharynx |
X: External |
3: Maribavir Anti-infective |
8: New Technology Group 8 |
| D: Mouth and Pharynx |
X: External |
6: Lefamulin Anti-infective |
6: New Technology Group 6 |
| D: Mouth and Pharynx |
X: External |
8: Uridine Triacetate |
2: New Technology Group 2 |
| D: Mouth and Pharynx |
X: External |
F: Other New Technology Therapeutic Substance J: Apalutamide Antineoplastic |
5: New Technology Group 5 |
| D: Mouth and Pharynx |
X: External |
J: Quizartinib Antineoplastic |
9: New Technology Group 9 |
| D: Mouth and Pharynx |
X: External |
K: Sabizabulin |
8: New Technology Group 8 |
| D: Mouth and Pharynx |
X: External |
L: Erdafitinib Antineoplastic |
5: New Technology Group 5 |
| D: Mouth and Pharynx |
X: External |
M: Baricitinib |
6: New Technology Group 6 |
| D: Mouth and Pharynx |
X: External |
N: SER-109 |
9: New Technology Group 9 |
| D: Mouth and Pharynx |
X: External |
R: Venetoclax Antineoplastic |
5: New Technology Group 5 |
| D: Mouth and Pharynx |
X: External |
R: Fostamatinib |
7: New Technology Group 7 |
| D: Mouth and Pharynx |
X: External |
T: Ruxolitinib V: Gilteritinib Antineoplastic |
5: New Technology Group 5 |
| G: Upper GI |
7: Via Natural or Artificial Opening |
3: Maribavir Anti-infective K: Sabizabulin |
8: New Technology Group 8 |
| G: Upper GI |
7: Via Natural or Artificial Opening |
M: Baricitinib |
6: New Technology Group 6 |
| G: Upper GI |
7: Via Natural or Artificial Opening |
R: Fostamatinib |
7: New Technology Group 7 |
| G: Upper GI |
8: Via Natural or Artificial Opening Endoscopic |
8: Mineral-based Topical Hemostatic Agent |
6: New Technology Group 6 |
| H: Lower GI |
7: Via Natural or Artificial Opening |
3: Maribavir Anti-infective K: Sabizabulin |
8: New Technology Group 8 |
| H: Lower GI |
7: Via Natural or Artificial Opening |
M: Baricitinib |
6: New Technology Group 6 |
| H: Lower GI |
7: Via Natural or Artificial Opening |
R: Fostamatinib |
7: New Technology Group 7 |
| H: Lower GI |
7: Via Natural or Artificial Opening |
X: Broad Consortium Microbiota-based Live Biotherapeutic Suspension |
8: New Technology Group 8 |
| H: Lower GI |
8: Via Natural or Artificial Opening Endoscopic |
8: Mineral-based Topical Hemostatic Agent |
6: New Technology Group 6 |
| Q: Cranial Cavity and Brain |
3: Percutaneous |
1: Eladocagene exuparvovec |
6: New Technology Group 6 |
| V: Bones |
0: Open |
P: Antibiotic-eluting Bone Void Filler |
7: New Technology Group 7 |
Back to ICD-10 PCS (Procedure) Home